相关实验视频
Updated: Jan 10, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
37.3K
在阿尔茨海默氏病中神经元功能障碍的分子和神经病理决定因素
Lazaro M Sanchez-Rodriguez1,2,3, Joon Hwan Hong1,2,3, Veronika Pak1,2,3
1Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
bioRxiv : the preprint server for biology
|November 24, 2025
概括
阿尔茨海默病 (AD) 显示了与认知衰退和神经病理学相关的神经刺激/抑制 (E/I) 不平衡. 确定了E/I比率的分子预测因素,为AD电路功能障碍提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 的特征是不明确的神经元刺激/抑制 (E/I) 不平衡.
- 了解E/I不平衡的生物学基础对于AD研究至关重要.
研究的目的:
- 在阿尔茨海默氏症 (AD) 中映射个体,全脑E / I失衡.
- 研究E/I比率,认知功能和神经病理学之间的关联.
- 确定区域E/I比率的分子预测因素.
主要方法:
- 使用死前功能神经成像和死后分子数据进行生物物理建模.
- 与认知表现,衰退和神经病理负担相关的E/I比率的分析.
- 在独立的队列中识别和验证E/I比率的基因和蛋白质预测因子.
主要成果:
- 高阶认知区域的E/I比率与认知表现和下降相关,由神经病理学介导.
- 在E/I比率和神经纤维状结严重程度之间发现了反转的U形关系.
- 89个基因和101个蛋白质被确定为区域E / I比率的预测因素,其中涉及突触和免疫通路.
- 与小质细胞和小质细胞前体细胞的细胞分布一致的E/I不平衡.
结论:
- 神经元E/I不平衡是阿尔茨海默病 (AD) 电路功能障碍的一个关键特征.
- 分子和细胞因素对E/I失衡和AD进展有显著的贡献.
- 这项研究提供了对AD中E/I不平衡的生物学基础的全面了解.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Role of Neurotransmitters in Memory
2.4K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.4K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K

